RP-008 + Varenicline for Trigeminal Neuralgia

(RELIEF Trial)

This trial tests a new treatment, RP-008, combined with varenicline (a medication often used to help people stop smoking), for individuals with trigeminal neuralgia (TN), a condition causing severe facial pain. Researchers aim to determine if this combination is safe, well-tolerated, and effective in reducing pain and the frequency of attacks. Participants will receive a single dose of RP-008, with varenicline and a corticosteroid (an anti-inflammatory medicine) administered before and after treatment. This trial suits those who have had TN for at least six months, experience pain in specific facial areas, and have not found relief with at least one standard medication. As a Phase 1 trial, this research focuses on understanding how the treatment works in people, offering participants the opportunity to be among the first to receive this new treatment.

The trial information does not specify if you need to stop taking your current medications. However, since the trial involves testing a new treatment, it's possible that changes to your medication might be required. Please consult with the trial coordinators for specific guidance.

Research is testing whether RP-008, combined with varenicline, is safe and effective for treating trigeminal neuralgia, a painful nerve condition. Limited information exists about RP-008, as the study remains in its early stages, so researchers closely monitor safety.

Varenicline, the other drug in the combination, has FDA approval to help people quit smoking, indicating its safety for that purpose. However, its use with RP-008 for trigeminal neuralgia is still under investigation.

Unlike traditional treatments for trigeminal neuralgia, which often include anticonvulsants like carbamazepine or surgical options, RP-008 offers a novel approach. It introduces a unique mechanism of action by combining with varenicline, typically used for smoking cessation, potentially targeting nerve pain differently. Researchers are excited about RP-008 because it may provide faster relief with a single dose combined with varenicline and corticosteroids, possibly reducing the need for long-term medication use and its associated side effects.

Participants in this trial will receive RP-008, which studies have shown may help reduce pain in people with trigeminal neuralgia (TN) when combined with varenicline. Trigeminal neuralgia causes intense facial pain. This combination targets the nerve signals that cause pain. Early research suggests it could provide relief by calming the nerve activity responsible for the pain. Although more research is needed, initial trials indicate this approach looks promising.¹²³⁶⁷